Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 09, 2024 15:34 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
April 09, 2024 12:00 ET
|
Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 08, 2024 11:36 ET
|
Revolution Medicines, Inc.
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...
Revolution Medicines to Participate in Upcoming Investor Conferences
April 04, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
March 28, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
March 27, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
[Latest] Global Fish Feed Market Size/Share Worth USD 7.2 Billion by 2032 at a 4.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 20, 2024 15:00 ET
|
Custom Market Insights
Austin, TX, USA, March 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Fish Feed Market Size, Trends and Insights By Product Type (Plant-Based, Fish...
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
March 11, 2024 08:00 ET
|
Immuneering Corporation
- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) - - Phase 2a portion of Phase...
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
March 06, 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
March 04, 2024 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...